NIH SBIR and STTR: Due Dates, Institutes and How to Choose

NIH, CDC and FDA run their small business programs through two parent announcements: PA-27-100 for SBIR (R43/R44) and PA-27-102 for STTR (R41/R42). Both accept applications on NIH's standard receipt dates and both are open to any small business whose project fits one of the participating institutes.

Who this fits and who it does not

The company must be a US for-profit small business, 500 employees or fewer including affiliates, more than 50% owned and controlled by US citizens or permanent residents (13 CFR 121.702, with the exceptions that rule allows, which at NIH include companies more than 50% owned by multiple venture capital operating companies, hedge funds or private equity firms), with the work performed in the US. PA-27-100 adds the SBIR rule that the small business should do most of the research and the PD/PI should be primarily employed by the small business. PA-27-102 is the route when the project depends on a formal collaboration with a nonprofit research institution, and STTR allows the PD/PI to be primarily employed by that institution.

• It fits a therapeutic, device, diagnostic, digital health or research tool company with preliminary data and a clear commercialization path.
• It fits a company whose scientific lead is a university researcher: that is what STTR is for.
• It does not fit a company that fails the ownership test. Those companies can still hold an NIH research grant; see NIH R01 and R21 for companies.
• Applicants that have received more than 20 Phase I awards over the past five fiscal years must meet the Transition Rate benchmark stated in the announcement.

How the process works

Standard receipt dates for SBIR and STTR are September 5, January 5 and April 5. The next one: January 5, 2027 (standard receipt dates September 5, January 5, April 5); PA-27-100 expires April 6, 2027. Applications go through Grants.gov and eRA Commons; the company needs SAM.gov, the SBA Company Registry, eRA Commons and Grants.gov accounts before the receipt date.

PA-27-100 accepts Phase I, Phase II, Direct to Phase II (NIH only) and Fast-Track (NIH only). Fast-Track submits Phase I and Phase II together as one application. Direct to Phase II is for a company that has already demonstrated feasibility without an NIH Phase I for that project.

Budgets follow the SBA guideline unless the institute sets its own: SBA Phase I guideline $335,937; institute ceilings up to $700,000 Phase I and $3,000,000 Phase II (see the announcement table). PA-27-100's table lists institute ceilings that differ, for example: National Cancer Institute $700,000 Phase I and $2,500,000 Phase II; National Heart, Lung, and Blood Institute $400,000 and $3,000,000; National Institute on Aging $700,000 and $3,000,000; National Institute of Allergy and Infectious Diseases $700,000 and $3,000,000; National Institute of Diabetes and Digestive and Kidney Diseases $400,000 and $2,500,000; National Eye Institute $400,000 Phase I. The full table is in the announcement and I read it for the specific institute before any budget is drafted.

Counting backward from a receipt date: registrations live first, the Specific Aims page agreed next, then the full application (about 7 pages of science plus the supplementary components) submitted in eRA Commons early enough to clear the error checks before the deadline.

My read

• Choose the institute by mission, then check its cap. A $700,000 Phase I ceiling at NCI, NIA or NIAID changes what a Phase I can attempt compared with the SBA guideline elsewhere.
• SBIR versus STTR is a question about where the PI sits and whether the university partner is doing real research, not about which is easier. STTR carries a required partner share of the work.
• NIH reviewers score the science first. Preliminary data, even from a small pilot, moves the score more than any market slide.
• A resubmission is normal at NIH. Plan for the summary statement, not just the first deadline.

Frequently asked questions

Which NIH institutes participate in PA-27-100?

The announcement's Components of Participating Organizations section lists them, together with CDC and FDA components. I confirm the institute and its ceiling in that section for each project.

Can a venture-backed company apply?

Under PA-27-100, yes: a company more than 50% owned by multiple venture capital operating companies, hedge funds or private equity firms can apply, with the certification the announcement requires, as long as no single such firm owns more than 50% unless it is itself a qualifying small business.

What if my PI is a professor?

Then the STTR parent, PA-27-102, is usually the route, since it allows the PD/PI to be primarily employed by the research institution and requires the formal collaboration SBIR does not.

Can a company apply for Direct to Phase II?

At NIH, yes, for a project that has demonstrated feasibility without a prior Phase I for that project. The announcement sets the documentation required.